眼防研究 | 1％阿托品每天使用副作用太大，那换成每周使用呢？

编者按

Q

这项研究回顾了3-15岁近视儿童每周使用1%阿托品超过一年的医疗记录，分析了眼轴长度（AL）和等效球镜屈光度（SER）的变化。通过广义估计方程分析了AL和SER随时间的变化，使用多元线性回归模型探讨了近视进展的相关因素。此外，研究还通过ROC分析评估了短期AL变化对预测阿托品“低反应者”（AL变化> 0.2mm/年）的表现。

Q

数据分析显示近视儿童在1年、2年、3年和4年的阿托品治疗期间，眼轴长度的累积变化分别为0.05mm、0.24mm、0.47mm和0.56mm。从第2年起，每年AL的延长约为0.20mm。球镜等效屈光度在第1年出现了0.21D的远视回退，2年、3年和4年的累积变化分别为-0.21D、-0.65D和-0.74D，显示每年SER约下降0.19D。每周使用1%阿托品与每日使用相比，效果相当，且能在4年内保持近视控制效果，副作用较为可控。此外，通过分层分析发现，年龄较大和初始近视度数较低的儿童，每周使用1%阿托品后近视进展较慢。同时，研究还发现，在治疗的前两个月内，若AL缩短超过0.04mm，可预测未来2年内快速进展者（AL变化>0.2mm/年），其敏感性和特异性分别为0.78和0.73。

表1

表2

Q

每周使用1%阿托品是一种有效且稳定的近视控制策略，尤其对屈光度（SER）在-1.00D以内的低度近视儿童效果更佳。该方案为低度近视儿童提供了新的近视防控选择。

参考文献

[1]Dong L, Kang YK, Li Y, et al. PREVALENCE AND TIME TRENDS OF MYOPIA IN CHILDREN AND ADOLESCENTS IN CHINA: A Systemic Review and Meta-Analysis. Retina. 2020 Mar;40(3):399-411.

[2]Sankaridurg P, Tahhan N, Kandel H, et al. IMI Impact of Myopia. Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):2.

[3]Hu Y, Ding X, Guo X, et al. Association of Age at Myopia Onset With Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020 Nov 1;138(11):1129-1134.

[4]Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology. 2016 Apr;123(4):697-708.

[5]McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt. 2013 May;33(3):373-378.

[6]Yen MY, Liu JH, Kao SC, et al. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989 May;21(5):180-2, 187.

[7]Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91.

[8]Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009 Mar;116(3):572-9.

[9]Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-399.

[10]Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019 Jan;33(1):3-13.

[11]Foo LL, Htoon H, Farooqui SZ, et al. Part-time use of 1% atropine eye drops for prevention of myopia progression in children. Int Ophthalmol. 2020 Jul;40(7):1857-1862.

[12]Expert consensus on the application of axial length in myopia prevention and control management (2023).Chin J Exp Ophthalmol, 2024, 42(1): 1-11.

[13]Zhu MJ, Feng HY, He XG,et al. The control effect of orthokeratology on axial length elongation in Chinese children with myopia. BMC Ophthalmol.

[14]Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019 Jan;126(1):113-124.

[15]Wei S, Li SM, An W, et al. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial. JAMA Ophthalmol. 2020 Nov 1;138(11):1178-1184.

[16]Zhu Q, Tang Y, Guo L, et al. Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children. Int J Med Sci. 2020 Jan 1;17(2):176-181.

[17]Han WT, Rong A, Xu W. Combination with different anticholinergic eyedrops for the treatment of children myopia. Zhonghua Yi Xue Za Zhi. 2019 Jun 25;99(24):1859-1863.

[18]Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020 Jul 29;10(1):12750.

[19]Tan Q, Ng AL, Choy BN, et al. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020 Sep;40(5):557-566.

[20]Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022 Mar;129(3):308-321.

[21]Polling JR, Tan E, Driessen S, et al. A 3-year follow-up study of atropine treatment for progressive myopia in Europeans. Eye (Lond). 2020 Nov;34(11):2020-2028.

[22]Ye L, Xu H, Shi Y, et al. Efficacy and Safety of Consecutive Use of 1% and 0.01% Atropine for Myopia Control in Chinese Children: The Atropine for Children and Adolescent Myopia Progression Study. Ophthalmol Ther. 2022 Dec;11(6):2197-2210.

[23]Yam JC, Jiang Y, Lee J, et al. The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine f

[24]Ye L, Shi Y, Yin Y, et al. Effects of Atropine Treatment on Choroidal Thickness in Myopic Children. Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):15.

[25]Nickla DL, Totonelly K, Dhillon B. Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks. Exp Eye Res. 2010;91(5):715–720.

[26]Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29(2):144–168.

[27]Carr BJ, Stell WK. Nitric oxide (NO) mediates the inhibition of form-deprivation myopia by atropine in chicks. Sci Rep. 2016;6(1):9.

[28]ZEISS. IOLMaster Technical Specifications. https://www.zeiss.com/meditec/en/products/optical-biometers/iolmaster-700-us/specifications-us.html#

[29]Chakraborty R, Read SA, Collins MJ. Diurnal variations in axial length, choroidal thickness, intraocular pressure, and ocular biometrics. Invest Ophthalmol Vis Sci. 2011 Jul 11;52(8):5121-5129.

[30]Read SA, Collins MJ, Iskander DR. Diurnal variation of axial length, intraocular pressure, and anterior eye biometrics. Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2911-2918.

[31]Li FF, Zhang Y, Zhang X, et al. Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Ophthalmology. 2021 Aug;128(8):1180-1187.

[32]Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012 Oct 11;53(11):7077-7085.

来源：“眼研社”微信公众号

审校：党委宣传办

上海市眼病防治中心

上海市眼科医院

同济大学附属眼科医院（筹）

上海市第一人民医院眼科

国家眼部疾病临床医学研究中心

地址：上海市康定路380号  / 虹桥路1440号

联系电话:021-62717733 / 021-62982727

我知道你在看哟